Patterns and Characterization of Acute Prescription Migraine Medication Use: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study (S59.008)

摘要: Objective: 1) To quantify and characterize use of acute prescription migraine medication (APMM) among respondents meeting criteria for in the United States. 2) migraine-related burden with respect to APMM status reasons never using APMM. Background: Appropriate prescribing is not optimal, claims-based analyses showing that 15%–43% those currently do receive medications. Design/Methods: This analysis longitudinal, Web-based Chronic Migraine Epidemiology Outcomes (CaMEO) Study data compared modified International Classification Headache Disorders, 2nd Edition criteria. Respondents were categorized by current treatment decisions, headache characteristics, headache-related disability. Results: 13,624 divided into users (n=3121 [22.9%]), lapsed (n=1719 [12.6%]), (n=8784 [64.5%]) Current had highest mean day frequency (7.3 days/month), rates physician-diagnosed (78.8%), moderate or severe disability (Migraine Disability Assessment grade III IV: 59.8%). Moderate was lower (41.8%) (28.8%). 46.7% used barbiturates opioids treat them on hand. Most common gave their headaches serious (53.2%), satisfactory response over-the-counter medications (42.6%), they did want take a (30.4%). Conclusions: The vast majority general population have As 28.8% this group has moderate/severe disability, many would benefit from these treatments. Among users, high opioid barbiturate reflect additional unmet needs. Disclosure: Dr. Hutchinson received personal compensation consulting, serving scientific advisory board, speaking, other activities Alder, Allergan, Amgen, Avanir, Biohaven, ElectroCore, Eli Lilly, Supernus, Teva. Lipton American Academy Neurology, Alder Biopharmaceuticals, Society, Autonomic Technologies, Avanir Pharmaceuticals, Biovision, Boston Scientific, Reddy’s, Electrocore, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Teva, Trigemina, Vector, Vedanta. holds stock and/or options Biohaven. Ailani Biohavin, Lilly Company, Promius, Impel, Satsuma, Aptus, Alpha Sites Miller Medical Communications. an editorial capacity Pain Reports (section editor). research support ARMR/American Foundation Reed Merck & Co., Inc., Promius. Allergan. Fanning Vedanta Research, funding directly Allergan work CaMEO Study. . Promius via grants National Foundation. Manack Adams Aubrey Adams, plc. plc which sponsored involved as investigator. Buse Reports.